Richardson Electronics (RELL) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
8 Jan, 2026Executive summary
Q2 FY26 net sales rose 5.7% year-over-year to $52.3M, marking the sixth consecutive quarter of YoY growth, led by 39% growth in GES and 28.1% in Canvys, while PMT sales declined 4%.
Excluding Healthcare, which was divested in January 2025, net sales increased 9% YoY; Healthcare results now consolidated into PMT.
Operating income improved to $0.1M from a $0.7M loss, and net loss narrowed to $0.1M from $0.8M; EBITDA for Q2 was $0.7M, up from breakeven.
First six months: net sales $106.9M (+3.6%), net income $1.8M vs. $0.2M loss, EBITDA $4.0M vs. $1.7M.
A quarterly cash dividend of $0.06 per share was declared.
Financial highlights
Q2 FY26 gross margin was 30.8%, slightly down from 31.0% YoY; operating expenses improved to 30.5% of sales.
Net loss per diluted share was $0.01, compared to $0.05 loss YoY; Q2 operating margin improved to 0.3% from -1.3%.
Cash and cash equivalents at quarter-end: $33.1M; no outstanding debt.
Backlog at quarter-end: $135.7M, up over 125% since FY2019.
Capital expenditures of $1.6M in Q2, focused on manufacturing, facilities, and IT.
Outlook and guidance
Anticipates continued growth in green energy and semiconductor wafer fab equipment markets through 2026 and beyond.
Expects bottom-line improvement in healthcare segment starting FY27 as ALTA tube production concludes and Siemens repair ramps up.
Ongoing investments in design centers, R&D, and new product development to support future growth.
Management expects continued earnings improvement and value creation for shareholders, citing a strong balance sheet and durable customer relationships.
Near-term volatility expected from global trade and U.S. policy impacts, but minimal exposure to China limits tariff risk.
Latest events from Richardson Electronics
- Sales and profits fell in 2024, but margin, cash flow, and backlog support a positive 2025 outlook.RELL
Q4 20242 Feb 2026 - Q1 FY25 sales up 2.2% to $53.7M, with GES and Healthcare growth and a strong, debt-free balance sheet.RELL
Q1 202519 Jan 2026 - Q3 net sales up 2.7% YoY, strong PMT/Canvys, $4.9M Healthcare loss, cash $36.7M, no debt.RELL
Q3 202516 Jan 2026 - Q2 FY25 sales up 12.1% to $49.5M, led by 129% GES growth and improved margins.RELL
Q2 202510 Jan 2026 - Shareholders will vote on director elections, auditor ratification, compensation, and capital structure changes.RELL
Proxy Filing1 Dec 2025 - Proxy seeks approval for director elections, auditor, compensation, and share increases.RELL
Proxy Filing1 Dec 2025 - Director elections, auditor ratification, and executive pay are key 2024 meeting topics.RELL
Proxy Filing1 Dec 2025 - Annual meeting to elect directors, ratify auditor, and approve executive pay on October 8, 2024.RELL
Proxy Filing1 Dec 2025 - Definitive proxy statement filed for shareholder voting, with no fee required.RELL
Proxy Filing1 Dec 2025